Profile: Genomic Health Inc (GHDX.OQ)
22 May 2019
Genomic Health, Inc., incorporated on August 22, 2000, is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and globally commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score (GPS), for prostate cancer.
The Company's offerings include Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test. Its Oncotype DX tests utilize quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT PCR), in standard tumor pathology specimens to provide tumor specific information, or the oncotype of a tumor. Its technologies allow it to analyze tumor tissue samples in its clinical reference laboratory and provide physicians with genomic information specific to the patient's tumor. It analyzes tissues that are handled, processed and stored under clinical pathology laboratory practices. As of December 31, 2016, more than 19,000 physicians in over 70 countries had ordered more than 700,000 Oncotype DX tests. All of its testing services are made available through its clinical reference laboratory located in Redwood City, California. Its Oncotype IQ Genomic Intelligence Platform product pipeline includes the planned development of products that relate to tumor monitoring for multiple cancer types.
The Company conducted studies of its Oncotype DX breast cancer test with clinical samples from postmenopausal women with invasive breast cancer who were treated with aromatase inhibitors. It has developed its gene panel by identifying 761 cancer related genes through review of existing research literature and computer analysis of genomic databases. The Oncotype DX prostate cancer test analyzes 17 genes across four biological pathways from tumor tissue removed during biopsy to provide an individual GPS, which in combination with other clinical factors, further clarifies a man's risk prior to treatment intervention. The Company uses its RT PCR process for analyzing very small amounts of fixed prostate tissue obtained by needle biopsy to determine, based on the biopsy, whether a patient has high grade disease or disease that has extended beyond the prostate versus low grade disease or disease confined to the prostate.
The Company competes with Agendia Inc., BioTheranostics, Exact Sciences, Inc. GenomeDx Biosciences Inc., Hologic Inc., Myriad Genetics Inc., NanoString Technologies Inc., NeoGenomics, Inc., Novartis AG, Qiagen N.V., Foundation Medicine, Grail, Guardant Health, MDxHealth, Metamark, Inc., Natera Inc. and Laboratory Corporation of America Holdings.
Genomic Health Inc
301 Penobscot Dr
REDWOOD CITY CA 94063-4700